News

September 25, 2017September 25, 2017

Disarm Therapeutics Receives Key Funding for ALS Therapy Development

Research into the development of new therapies to treat several traumatic, inflammatory, and neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) received an important financial boost with the announcement by Disarm Therapeutics that ... Read more

September 22, 2017September 22, 2017

FDA Grants Orphan Drug Status to RNS60 for ALS Treatment

News

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Revalesio’s investigational drug RNS60 to treat amyotrophic lateral sclerosis (ALS). The status gives incentives for companies to develop new therapies ... Read more

September 21, 2017September 24, 2017

FDA Grants Orphan Drug Status to Amylyx’s AMX0035 for Treatment of ALS

News

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals, the drug developer, announced in a press release. Orphan ... Read more

September 20, 2017

Cell Cleaning Mechanism Has Dual Role in ALS, Study Finds

News

A mechanism that cells normally use to keep them healthy was found to have a dual role in amyotrophic lateral sclerosis (ALS). While the process, called autophagy, delays disease progression ... Read more

September 19, 2017September 19, 2017

In New Book, ALS Researcher Niels Birbaumer Explores Brain’s Limitless Capacity to Remodel Itself

News

Neuroscientist and professor Niels Birbaumer, a senior research fellow at Switzerland’s Wyss Center in Geneva, has written a new book investigating the brain’s seemingly limitless capacity to reshape itself and ... Read more

September 18, 2017September 18, 2017

DNA Damage and Other Pathologies Absent in a Mouse Model of Familial ALS, German Study Shows

News

Severe DNA damage and other disease-associated hallmarks are absent in a mouse model of familial amyothrophic lateral sclerosis (fALS), a new study shows. The study, “DNA strand breaks and ... Read more

September 15, 2017September 15, 2017

First Trial of Potential ALS Gene Therapy VM202 Shows Treatment’s Safety

News

The investigational gene therapy VM202, developed by VM BioPharma and intended for the treatment of amyotrophic lateral sclerosis (ALS), has been shown to be safe and well-tolerated in a small Phase ... Read more

September 14, 2017

National Institutes of Health Awards $30 Million to Support Development of 3-D Models of Disease

News

The National Institutes of Health has awarded $30 million over two years to 13 researchers who are developing three-dimensional models of amyotrophic lateral sclerosis and other diseases. Researchers say the initiative is ... Read more

September 13, 2017

Human Skin Cells Successfully Converted into Motor Neurons

News

Scientists have discovered how adult skin cells can be converted into motor neurons without transitioning them through a stem cell state. The findings promise to help researchers better understand ... Read more

September 12, 2017September 12, 2017

Amylyx, Project ALS Collaborate on Preclinical Study to Test AMX0035 as Potential ALS Therapy

News

Project ALS and Amylyx Pharmaceuticals will collaborate on preclinical studies of Amylyx’s lead compound AMX0035 as a potential treatment for patients with amyotrophic lateral sclerosis (ALS). These studies will complement Amylyx’s recently ... Read more